Personalised Medicines innovation in Europe

0
879
foto Lorenzin

Combine the innovation of the so-called “personalised medicines” with investment in research and the sustainability of public health systems. This is the challenge that involves all European governments and that was launched at the workshop “Adaptive Pathways for Personalised Medicines – Supporting Innovation in Europe” organized dall’Ebe (European Biopharmaceutical Enterprises) and by the Italian Embassy, which was held today in London at the Institute of Italian Culture.

 

The meeting was attended by the Health Minister Beatrice Lorenzin, Italian Ambassador Pascuale Terracciano, Sergio Pecorelli, director of AIFA (Italian pharmaceutical agency), Luca Pani, Chief executive of Aifa  as well as sixty guest Italian and English, with speakers who also come from France, Belgium, Canada and Hungary.  There were also presented institutions such as the European Community, the Ema (European Medicines Agency), representatives of the academic and research facilities, hospitals and medical industries who support research. “It’s time for a change of pace, to share with the business strategies and objectives of the research, because we share the goal: to ensure the best care within a system that become sustainable”, said Health Minister Beatrice Lorenzin. She added: “ The pharmaceutical sector is strategical, we need to integrated our excellence and tradition in a future scenario. Referring to the european programme “Horizon 2020”, ‘the research program just launched by the European union Beatrice  Lorenzin said: “ This workshop have a particularly worth, as a preparatory event of the Italian Presidency of the EU in 2014, I believe Italy,  in that period, have to  promote a new legislation for innovation in Europe”.

Agnes Mathieu, member of Europen Commission said: “Personalized medicine is an increase area where we need to invest. It has the potential to offer new benefit for the patient including better target treatment”. She added: “ As European Union, we need to ensure an appropriate level of safety and performance of these tests,  to broaden the definition of Ivd (In vitro diagnostic), and to do a revision of the clinical trial directive”.

Daniela Couto, Ceo at Cell2b, a biotechnology star-up dedicated to the development of a new line of healthcare therapies to treat organ rejection in patients undergoing transplants, underlined: “ Two topic are crucial for us: adaptive tools and adaptive license.  Firstly, we are moving to a really expensive area for companies, so we need to find a way to keep attractive companies in order to invest in Europe; secondly, we need to  invest in health research in order to answer at scientific question we are looking for.

 

LEAVE A REPLY